Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) fell 2.9% during trading on Tuesday . The stock traded as low as $8.66 and last traded at $8.73, with a volume of 317,306 shares trading hands. The stock had previously closed at $8.99.

Several brokerages have commented on HALO. Wells Fargo & Co. reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Canaccord Genuity restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Jefferies Group restated a “sell” rating and issued a $6.75 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $15.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, June 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $15.68.

The stock’s market capitalization is $1.11 billion. The stock has a 50-day moving average price of $8.95 and a 200-day moving average price of $9.59.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.04. The company earned $42.50 million during the quarter, compared to the consensus estimate of $29.65 million. Halozyme Therapeutics’s quarterly revenue was up 127.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.12) EPS. On average, equities analysts forecast that Halozyme Therapeutics Inc. will post ($1.03) earnings per share for the current year.

Other institutional investors have added to or reduced their stakes in the company. Tekla Capital Management LLC acquired a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $3,466,000. BB Biotech AG raised its position in Halozyme Therapeutics by 1.4% in the fourth quarter. BB Biotech AG now owns 7,029,832 shares of the biopharmaceutical company’s stock valued at $121,827,000 after buying an additional 100,000 shares in the last quarter. California Public Employees Retirement System raised its position in Halozyme Therapeutics by 10.2% in the fourth quarter. California Public Employees Retirement System now owns 255,600 shares of the biopharmaceutical company’s stock valued at $4,430,000 after buying an additional 23,600 shares in the last quarter. New York State Common Retirement Fund raised its position in Halozyme Therapeutics by 5.4% in the fourth quarter. New York State Common Retirement Fund now owns 372,785 shares of the biopharmaceutical company’s stock valued at $6,460,000 after buying an additional 18,940 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in Halozyme Therapeutics by 9.8% in the fourth quarter. ProShare Advisors LLC now owns 122,509 shares of the biopharmaceutical company’s stock valued at $2,123,000 after buying an additional 10,937 shares in the last quarter.

Halozyme Therapeutics, Inc is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.